Use of metformin in polycystic ovary syndrome

American Journal of Obstetrics and Gynecology

Volumn 199, Issue 6, 2008, Pages 596-609

  Mathur, Ruchi ^a   Alexander, Carolyn J ^c   Yano, Jacqueline ^a   Trivax, Bradley ^b   Azziz, Ricardo ^a,b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NONE

Author keywords

infertility; insulin resistance; metformin; polycystic ovary syndrome; pregnancy

Indexed keywords

ANDROGEN; ANDROSTENEDIONE; CLOMIFENE CITRATE; CYPROTERONE ACETATE; ETHINYLESTRADIOL; FLUTAMIDE; GLITAZONE DERIVATIVE; GONADORELIN AGONIST; GONADOTROPIN DERIVATIVE; INSULIN; INSULIN SENSITIZING AGENT; METFORMIN; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT; PIOGLITAZONE; PLACEBO; PROGESTERONE; RECOMBINANT FOLLITROPIN; ROSIGLITAZONE; TESTOSTERONE; TROGLITAZONE;

ABDOMINAL DISCOMFORT; ABDOMINAL OBESITY; BLOATING; BODY MASS; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; COUGHING; CYANOCOBALAMIN DEFICIENCY; DIARRHEA; DIET RESTRICTION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG POTENTIATION; DRUG WITHDRAWAL; DYSLIPIDEMIA; ENDOMETRIUM BIOPSY; EVENING DOSAGE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; FLATULENCE; FLUSHING; GASTROINTESTINAL TOXICITY; HEARTBURN; HIRSUTISM; HUMAN; HYPERINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; INDIGESTION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRACYTOPLASMIC SPERM INJECTION; INTRAUTERINE INSEMINATION; LACTIC ACIDOSIS; LIVER DYSFUNCTION; LOW DRUG DOSE; METABOLIC SYNDROME X; METALLIC TASTE; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OLIGOMENORRHEA; OLIGOOVULATORY INFERTILITY; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PREGNANCY DIABETES MELLITUS; PREGNANCY OUTCOME; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; REVIEW; RHINORRHEA; SIDE EFFECT; SNEEZING; SPONTANEOUS ABORTION; SUBFERTILITY; TASTE DISORDER; THORAX PAIN; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

ADOLESCENT; ADULT; CLOMIPHENE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; INFERTILITY, FEMALE; INSULIN RESISTANCE; METFORMIN; OVULATION; POLYCYSTIC OVARY SYNDROME; PREGNANCY; PREGNANCY RATE; PREGNANCY, HIGH-RISK; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; THIAZOLIDINEDIONES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 57149142767     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2008.09.010     Document Type: Review

References (109)

1. Stein I., and Leventhal M. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 29 (1935) 181-191
2. Azziz R., Sanchez L.A., Knochenhauer E.S., et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab 89 (2004) 453-462
3. Yildiz B.O., Knochenhauer E.S., and Azziz R. Impact of obesity on the risk for polycystic ovary syndrome. J Clin Endocrinol Metab 93 (2008) 162-168
4. Azziz R., Marin C., Hoq L., Badamgarav E., and Song P. Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. J Clin Endocrinol Metab 90 (2005) 4650-4658
5. Legro R.S. Pregnancy considerations in women with polycystic ovary syndrome. Clin Obstet Gynecol 50 (2007) 295-304
6. Burghen G.A., Givens J.R., and Kitabchi A.E. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 50 (1980) 113-116
7. DeUgarte C.M., Barolucci A.A., and Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril 83 (2005) 1454-1460
8. Jonard S., and Dewailly D. The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest. Hum Reprod Update 10 (2004) 107-117
9. Franks S., Gilling-Smith C., Watson H., and Willis D. Insulin action in the normal and polycystic ovary. Endocrinol Metab Clin North Am 28 (1999) 361-378
10. Legro R.S., Finegood D., and Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 83 (1998) 2694-2698
11. Ehrmann D.A. Polycystic ovary syndrome. N Engl J Med 352 (2005) 1223-1236
12. Talbott E.O., Zborowski J.V., Boudreaux M.Y., McHugh-Pemu K.P., Sutton-Tyrrell K., and Guzick D.S. The relationship between C-reactive protein and carotid intima-media wall thickness in middle-aged women with polycystic ovary syndrome. J Clin Endocrinol Metab 89 (2004) 6061-6067
13. Talbott E.O., Zborowski J.V., Rager J.R., Boudreaux M.Y., Edmundowicz D.A., and Guzick D.S. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab 89 (2004) 5454-5461
14. Legro R.S., Azziz R., Ehrmann D., Fereshetian A.G., O'Keefe M., and Ghazzi M.N. Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone. J Clin Endocrinol Metab 88 (2003) 5137-5144
15. Ehrmann D.A., Liljenquist D.R., Kasza K., et al. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 91 (2006) 48-53
16. Essah P.A., Wickham E.P., and Nestler J.E. The metabolic syndrome in polycystic ovary syndrome. Clin Obstet Gynecol 50 (2007) 205-225
17. Norman R.J., Davies M.J., Lord J., and Moran L.J. The lifestyle modification in polycystic ovary syndrome. Trends Endocrinol Metab 13 (2002) 251-257
18. Balen A.H. PCOS, obesity, and reproductive function: RCOG special study group on obesity (2007), RCOG Press, London
19. Hoeger K.M. Exercise therapy in polycystic ovary syndrome. Semin Reprod Med 26 (2008) 93-100
20. Ehrmann D., Schneider D.J., and Sobel B.E. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 82 (1997) 2108-2116
21. Dunaif A., Scott D., Finegood D., Quintana B., and Whitcomb R. The insulin sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 81 (1996) 3299-3306
22. Azziz R., Ehrmann D.A., Legro R.S., et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 86 (2001) 1626-1632
23. Sepilian V., and Nagamani M. Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance. J Clin Endocrinol Metab 90 (2005) 60-65
24. Nestler J.E. Metformin for the treatment of the polycystic ovary syndrome. N Engl J Med 358 (2008) 47-54
25. Tan S., Hahn S., Benson S., et al. Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance. Eur J Endocrinol 157 (2007) 669-676
26. Bailey C., and Turner R. Metformin. N Engl J Med 334 (1996) 574-579
27. Morin-Papunen L.C., Koivunen R.M., Ruokonen A., and Martikainen H.K. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril 69 (1998) 691-696
28. Musi N., Hirshmen M.F., Nygren J., et al. Metformin increases AMP activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 51 (2002) 2074-2081
29. Zhou G., Myers R., Li Y., Chen Y., and Shen X. Role of AMP activated protein kinase in mechanism of metformin action. J Clin Invest 108 (2001) 1167-1174
30. Zou M.H., Kirkpatrick S.S., Davis B.J., et al. Activation of the AMP activated protein kinase by the anti-diabetic drug metformin in vivo. J Biol Chem 279 (2004) 43940-43951
31. Elia E., Sander V., Luchetti C.G., Solano M.E., Di Girolamo G., Gonzalez C., and Motta A.B. The mechanisms involved in the action of metformin in regulating ovarian function in hyperandrogenized mice. Mol Hum Reprod 12 (2006) 475-481
32. Cibula D., Fanta M., Vrbikova J., et al. The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenemia, SHBG and lipids in PCOS patients. Hum Reprod 20 (2005) 180-184
33. Arlt W., Auchus R.J., and Miller W.L. Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3 beta- hydroxysteroid dehydrogenase. J Biol Chem 276 (2001) 16767-16771
34. Barbieri R.L. Metformin for treatment of the polycystic ovary syndrome. Obstet Gynecol 101 (2003) 785-793
35. Glueck C.J., Wang P., Goldenberg N., and Sieve-Smith L. Pregnancy outcomes among women with polycystic ovary syndrome with metformin. Hum Reprod 17 (2002) 2858-2864
36. Pasquali R., Gambineri A., Biscotti D., et al. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without polycystic ovary syndrome. J Clin Endocrinol Metab 85 (2000) 2767-2774
37. Barbieri R.L. Clomiphene versus metformin for ovulation induction in polycystic ovary syndrome: the winner is.... J Clin Endocrinol Metab 92 (2007) 3399-3401
38. Shaw R.J., Lamia K.A., Vasquez D., et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310 (2005) 1642-1646
39. Nestler J.E., and Jakubowicz D.J. Decreases in ovarian cytochrome P-450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 335 (1996) 617-623
40. Lord J.M., Flight I.H., and Norman R.J. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 327 (2003) 951-953
41. Legro R.S., Barnhart H.X., Schlaff W.D., et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 356 (2007) 551-566
42. Creanga A.A., Bradley H.M., McCormick C., and Witkop C.T. Uses of metformin in polycystic ovary syndrome: a meta analysis. Obstet Gynecol 111 (2008) 959-968
43. Moll E., Bossuyt P.M.M., Korevaar J.C., Lambalk C.B., and van der Veen F. Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomized double blind clinical trial. BMJ 332 (2006) 1461-1462
44. Zain M.M., Jamaluddin R., Ibrahim A., and Norman R.J. Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertil Steril (2008) Mar 3 [Epub ahead of print]
45. Vandermolen D.T., Ratts V.S., Evans W.S., Stoval D.W., Kauma S.W., and Nestler J.E. Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil Steril 75 (2001) 310-315
46. Sonntag B., Gotte M., Wiilfing P., Schuring A.N., Kiesel L., and Greb R.R. Metformin alters insulin signaling and viability of human granulosa cells. Fertil Steril 84 (2005) 1173-1179
47. Seibel S.A., Chou K.H., Capp E., Spritzer P.M., and von Eye Corleta H. Effect of metformin on IGF-1 and IGFBP-1 levels in obese patients with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 138 (2008) 122-124
48. Tosca L., Chabrolle C., Svetlana U., and Dupont J. Effects of metformin on bovine granulosa cells steroidogenesis: possible involvement of adenosine 5' monophosphate-activated protein kinase (AMPK). Biol Reprod 76 (2007) 368-378
49. Kocak M., Caliskan E., Simsir C., and Haberal A. Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate resistant women with polycystic ovary syndrome. Fertil Steril 77 (2002) 101-106
50. Malkawi H.Y., and Qublan H.S. The effect of metformin plus clomiphene citrate on ovulation and pregnancy rates in clomiphene-resistant women with polycystic ovary syndrome. Saudi Med J 23 (2002) 663-666
51. Hwu Y.M., Lin S.Y., Huang W.Y., Lin M.H., and Lee R.K. Ultra-short metformin pretreatment for clomiphene citrate-resistant polycystic ovary syndrome. Int J Gynaecol Obstet 90 (2005) 39-43
52. Rouzi A.A., and Ardawi M.S. A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metformin and clomiphene citrate in women with clomiphene citrate-resistant polycystic ovary syndrome. Fertil Steril 85 (2006) 428-435
53. Baillargeon J.P., Jakubowicz D.J., Iuorno M.J., Jakubowicz S., and Nestler J.E. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril 82 (2004) 893-902
54. Van Santbrink E.J.P., Hohmann F.P., Eijkemans M.J.C., Laven J.S.E., and Fauser B.C.J. Does metformin modify ovarian responsiveness during exogenous FSH ovulation induction in normogonadotrophic anovulation?. A placebo-controlled double-blind assessment. Eur J Endocrinol 152 (2005) 611-617
55. Yarali H., Yildiz B.O., Demirol A., et al. Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial. Hum Reprod 17 (2002) 289-294
56. Palomba S., Falbo A., Orio Jr. F., et al. A randomized controlled trial evaluating metformin pre-treatment and co-administration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination. Hum Reprod 20 (2005) 2879-2886
57. Tang T., Glanville J., Orsi N., Barth J.H., and Balen A.H. The use of metformin for women with PCOS undergoing IVF treatment. Hum Reprod 21 (2006) 1416-1425
58. Costello M.F., Chapman M., and Conway U. A systematic review and meta-analysis of randomized controlled trials on metformin co-administration during gonadotropin ovulation induction or IVF in women with polycystic ovary syndrome. Hum Reprod 21 (2006) 1387-1399
59. Chang W.Y., Knochenhauer E.S., Bartolucci A.A., and Azziz R. Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups. Fertil Steril 83 (2005) 1717-1723
60. Genazzani A.D., Lanzoni C., Ricchieri F., Baraldi E., Casarosa E., and Jasonni V.M. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia. Gynecol Endocrinol 23 (2007) 146-152
61. Moghetti P., Castello R., Negri C., et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 85 (2000) 139-146
62. Legro R.S., Barnhart H.X., Schlaff W.D., et al. Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene. J Clin Endocrinol Metab 93 (2008) 792-800
63. Moll E., van der Veen F., and van Wely M. The role of metformin in polycystic ovary syndrome: a systematic review. Hum Reprod Update 13 (2007) 527-537
64. Giudice L.C. Endometrium in PCOS: implantation and predisposition to endocrine CA. Best Pract Res Clin Endocrinol Metab 20 (2006) 235-244
65. Jakubowicz D.J., Seppala M., Jakubowicz S., et al. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin-like growth factor-binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. J Clin Endocrinol Metab 86 (2001) 1126-1133
66. Jakubowicz D.J., Iuorno M.J., Jakubowicz S., Roberts K.A., and Nestler J.E. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 87 (2002) 524-529
67. Palomba S., Russo T., Orio Jr. F., et al. Uterine effects of metformin administration in anovulatory women with polycystic ovary syndrome. Hum Reprod 21 (2006) 457-465
68. Legro R.S., Zaino R.J., Demers L.M., et al. The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome. Am J Obstet Gynecol 196 (2007) 402.e1-402.e10
69. Lord J.M., Flight I.H., and Norman R.J. Insulin-sensitizing drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev 3 (2003) CD003053. Review
70. Glueck C.J., Phillips H., Cameron D., Sieve-Smith L., and Wang P. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil Steril 75 (2001) 46-52
71. Petitti D.B. Combination estrogen-progestin oral contraceptives. N Engl J Med 349 (2003) 1443-1450
72. Gilbert C., Valois M., and Koren G. Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis. Fertil Steril 86 (2006) 658-663
73. Glueck C.J., Goldenberg P., Wang P., Loftspring M., and Sherman A. Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout pregnancy. Hum Reprod 19 (2004) 510-521
74. Kovo M., Weissman A., Gur D., Levran D., Rotmensch S., and Glezerman M. Neonatal outcome in polycystic ovarian syndrome patients treated with metformin during pregnancy. J Matern Fetal Neonatal Med 19 (2006) 415-419
75. Hellmuth E., Damm P., and Molsted-Pedersen L. Oral hypoglycemic agents in 118 diabetic pregnancies. Diabet Med 17 (2000) 507-511
76. Velazquez E.M., Mendoza S., Hamer T., Sosa F., and Glueck C.J. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 43 (1994) 647-654
77. Nawrocka J., and Starczewski A. Effects of metformin treatment in women with polycystic ovary syndrome depends on insulin resistance. Gynecol Endocrinol 23 (2007) 231-237
78. Marcondes J.A., Yamashita S.A., Maciel G.A., Baracat E.C., and Halpern A. Metformin in normal-weight hirsute women with polycystic ovary syndrome with normal insulin sensitivity. Gynecol Endocrinol 23 (2007) 273-278
79. Sahin I., Serter R., Karakurt F., et al. Metformin versus flutamide in the treatment of metabolic consequences of non-obese young women with polycystic ovary syndrome: a randomized prospective study. Gynecol Endocrinol 19 (2004) 115-124
80. Yilmaz M., Biri A., Karakoc A., et al. The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome. J Endocrinol Invest 28 (2005) 1003-1008
81. Ortega-Gonzalez C., Luna S., Hernandez L., et al. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. J Clin Endocrinol Metab 90 (2005) 1360-1365
82. Deplewski D., and Rosenfield R.L. Role of hormones in pilosebaceous unit development. Endocr Rev 21 (2000) 363-392
83. Kolodziejczyk B., Duleba A.J., Spaczynski R.Z., and Pawelczyk L. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril 73 (2000) 1149-1154
84. Kelly C.J., and Gordon D. The effect of metformin on hirsutism in polycystic ovary syndrome. Eur J Endocrinol 147 (2002) 217-221
85. Morin-Papunen L.C., Vauhkonen I., Koivunen R.M., Ruokonen A., Martikainen H.K., and Tapanainen J.S. Endocrine and metabolic effects of metformin versus ethinyl-estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 85 (2000) 3161-3168
86. Luque-Ramirez M., Alvarez-Blasco F., Botella-Carretero J.I., Martinez-Bermejo E., Lasuncion M.A., and Escobar-Morreale H.F. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome. J Clin Endocrinol Metab 92 (2007) 2453-2461
87. Harborne L., Fleming R., Lyall H., Sattar N., and Norman J. Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. J Clin Endocrinol Metab 88 (2003) 4116-4123
88. Gambineri A., Patton L., Vaccina A., et al. Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. J Clin Endocrinol Metab 91 (2006) 3970-3980
89. Ehrmann D.A., Barnes R.B., Rosenfield R.L., Cavaghan M.K., and Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22 (1999) 141-146
90. Legro R.S., Kunselman A.R., Dodson W.C., and Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84 (1999) 165-169
91. Legro R.S., Gnatuk C.L., Kunselman A.R., and Dunaif A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab 90 (2005) 3236-3242
92. Palomba S., Falbo A., Russo T., et al. Insulin sensitivity after metformin suspension in normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab 92 (2007) 3128-3135
93. Harborne L.R., Sattar N., Norman J.E., and Fleming R. Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. J Clin Endocrinol Metab 90 (2005) 4593-4598
94. Salpeter S.R., Buckley N.S., Kahn J.A., and Salpeter E.E. Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am J Med 121 (2008) 149-157
95. Korytkowski M.T., Mokan M., Horwitz M.J., and Berga S.L. Metabolic effects of oral contraceptives in women with polycystic ovary syndrome. J Clin Endocrinol Metab 80 (1995) 3327-3334
96. Morin-Papunen L.C., Vauhkonen I., Koivunen R.M., Ruokonen A., Martikainen H.K., and Tapanainen J.S. Metformin versus ethinyl-estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized trial. J Clin Endocrinol Metab 88 (2003) 148-156
97. Costello M., Shrestha B., Eden J., Sjoblom P., and Johnson N. Insulin-sensitizing drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst Rev 1 (2007) CD005552
98. Elter K., Imir G., and Durmusoglu F. Clinical, endocrine and metabolic effects of metformin added to ethinyl-estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Hum Reprod 17 (2002) 1729-1737
99. Knowler W.C., Barrett-Connor E., Fowler S.E., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002) 393-403
100. Sharma S.T., Wickham III E.P., and Nestler J.E. Changes in glucose tolerance with metformin treatment in polycystic ovary syndrome: a retrospective analysis. Endocr Pract 13 (2007) 373-379
101. Tang T., Glanville J., Hayden C.J., White D., Barth J.H., and Balen A.H. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome: a randomized, placebo-controlled, double-blind multicenter study. Hum Reprod 21 (2006) 80-89
102. Meyer C., McGrath B.P., and Teede H.J. Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care 30 (2007) 471-478
103. Lakhani K., Prelevic G.M., Seifalian A.M., Atiomo W.U., and Hardiman P. Polycystic ovary syndrome, diabetes and cardiovascular disease: risk and risk factors. J Obstet Gynaecol 24 (2004) 613-621
104. Rautio K., Tapanainen J.S., Ruokonen A., and Morin-Papunen L.C. Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome. Eur J Endocrinol 152 (2005) 269-275
105. Tarkun I., Cetinarslan B., Turemen E., Sahin T., Canturk Z., and Komsuoglu B. Effects of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome. Eur J Endocrinol 153 (2005) 115-119
106. Topcu S., Tok D., Caliskan M., et al. Metformin therapy improves coronary microvascular function in patients with polycystic ovary syndrome and insulin resistance. Clin Endocrinol (Oxf) 65 (2006) 75-80
107. Diamanti-Kandarakis E., Paterakis T., Alexandraki K., et al. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reprod 21 (2006) 1426-1431
108. Morin-Papunen L.C., Rautio K., Ruokonen A., Hedberg P., Puukka M., and Tapanainen J.S. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88 (2003) 4649-4654
109. Salley K.E.S., Wickham E.P., Cheang K.I., Essah P.A., Karjane N.W., and Nestler J.E. Glucose intolerance in polycystic ovary syndrome-a position statement of the Androgen Excess Society. J Clin Endocrinol Metab 92 (2007) 4546-4556